Status:

COMPLETED

Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer

Lead Sponsor:

Anglo Celtic Cooperative Oncology Group

Conditions:

Breast Cancer

Infertility

Eligibility:

FEMALE

Phase:

PHASE3

Brief Summary

RATIONALE: Goserelin may help prevent early menopause in patients undergoing chemotherapy for breast cancer. It is not yet known whether goserelin is effective in preventing early menopause in women u...

Detailed Description

OBJECTIVES: Primary * Compare the incidence of premature ovarian failure after chemotherapy in premenopausal women with stage I-III breast cancer treated with goserelin vs no goserelin . Secondary ...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed invasive breast cancer
  • Stages I-IIIB with node-positive or -negative disease (N0-2)
  • Operable disease
  • Must meet 1 of the following criteria:
  • Has undergone mastectomy or breast-conserving surgery with complete excision of primary tumor within the past 8 weeks
  • Scheduled to receive neoadjuvant chemotherapy
  • No metastatic breast cancer, including supraclavicular fossa metastases
  • Hormone receptor status meeting 1 of the following criteria:
  • Estrogen receptor (ER) and progesterone receptor poor or negative AND not a candidate for adjuvant endocrine therapy
  • ER positive AND no requirement for ovarian suppression as a necessary part of treatment
  • PATIENT CHARACTERISTICS:
  • Female
  • Premenopausal with regular menses in the 12 months preceding surgery
  • No other prior or concurrent invasive malignancy except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • Suitable fitness status for chemotherapy
  • Adequate hepatic, renal, and bone marrow function
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior chemotherapy or endocrine therapy

Exclusion

    Key Trial Info

    Start Date :

    August 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    400 Patients enrolled

    Trial Details

    Trial ID

    NCT00427245

    Start Date

    August 1 2004

    Last Update

    August 7 2013

    Active Locations (66)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 17 (66 locations)

    1

    Basingstoke and North Hampshire NHS Foundation Trust

    Basingstoke, England, United Kingdom, RG24 9NA

    2

    Royal United Hospital

    Bath, England, United Kingdom, BA1 3NG

    3

    Frenchay Hospital

    Bristol, England, United Kingdom, BS16 1LE

    4

    Addenbrooke's Hospital

    Cambridge, England, United Kingdom, CB2 2QQ